In more innovative strategies, researchers attempt to design CAR T cells that are not only resistant to TGF-β but also become activated upon TGF-β exposure to enhance anti-tumor responses.22-24 These CAR T cells express a chimeric receptor composed of an ectodomain, a transmembrane domain, and an endodomain, which is the functional signaling portion of the receptor. This evidence concerns the gene TGFB1 and neoplasm.